Barclays’s Boston Scientific BSX Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$196M Sell
4,584,260
-439,897
-9% -$23.9M 0.04% 306
2026
Q1
$315M Buy
5,024,157
+663,465
+15% +$53.1M 0.08% 193
2025
Q4
$416M Sell
4,360,692
-159,259
-4% -$15.6M 0.1% 152
2025
Q3
$441M Buy
4,519,951
+152,500
+3% +$15.8M 0.1% 146
2025
Q2
$469M Sell
4,367,451
-1,168,302
-21% -$118M 0.11% 119
2025
Q1
$558M Buy
5,535,753
+1,121,449
+25% +$113M 0.16% 89
2024
Q4
$394M Buy
4,414,304
+339,068
+8% +$29.8M 0.11% 121
2024
Q3
$342M Buy
4,075,236
+83,063
+2% +$6.55M 0.09% 159
2024
Q2
$307M Sell
3,992,173
-54,345
-1% -$3.98M 0.09% 160
2024
Q1
$277M Buy
4,046,518
+671,795
+20% +$43.2M 0.1% 180
2023
Q4
$195M Sell
3,374,723
-798,464
-19% -$42.6M 0.07% 242
2023
Q3
$220M Buy
4,173,187
+413,994
+11% +$21.7M 0.14% 160
2023
Q2
$203M Buy
3,759,193
+2,461,951
+190% +$129M 0.13% 155
2023
Q1
$64.9M Sell
1,297,242
-901,779
-41% -$42.5M 0.03% 366
2022
Q4
$102M Buy
2,199,021
+573,278
+35% +$24.8M 0.05% 272
2022
Q3
$63M Buy
1,625,743
+227,034
+16% +$9.11M 0.07% 254
2022
Q2
$52.1M Sell
1,398,709
-645,611
-32% -$26.3M 0.03% 381
2022
Q1
$90.5M Sell
2,044,320
-607,129
-23% -$26.3M 0.07% 266
2021
Q4
$113M Sell
2,651,449
-169,696
-6% -$7.13M 0.04% 321
2021
Q3
$122M Buy
2,821,145
+703,594
+33% +$31.1M 0.06% 271
2021
Q2
$90.5M Buy
2,117,551
+523,967
+33% +$22M 0.04% 321
2021
Q1
$61.6M Buy
1,593,584
+12,069
+0.8% +$457K 0.03% 384
2020
Q4
$56.9M Sell
1,581,515
-53,384
-3% -$1.92M 0.03% 423
2020
Q3
$62.5M Buy
1,634,899
+634,665
+63% +$24.5M 0.04% 342
2020
Q2
$35.1M Sell
1,000,234
-1,940,660
-66% -$69.9M 0.03% 427
2020
Q1
$96M Buy
2,940,894
+733,795
+33% +$28.7M 0.08% 175
2019
Q4
$99.8M Buy
2,207,099
+275,882
+14% +$11.5M 0.06% 279
2019
Q3
$78.6M Sell
1,931,217
-90,243
-4% -$3.82M 0.05% 305
2019
Q2
$86.9M Buy
2,021,460
+489,526
+32% +$18.8M 0.05% 307
2019
Q1
$58.8M Buy
1,531,934
+173,943
+13% +$6.64M 0.04% 396
2018
Q4
$48M Sell
1,357,991
-248,633
-15% -$9.02M 0.04% 395
2018
Q3
$61.9M Sell
1,606,624
-435,464
-21% -$15.2M 0.04% 337
2018
Q2
$66.8M Sell
2,042,088
-121,996
-6% -$3.68M 0.06% 277
2018
Q1
$59.1M Sell
2,164,084
-139,527
-6% -$3.79M 0.05% 355
2017
Q4
$57.1M Buy
2,303,611
+1,429,713
+164% +$39.4M 0.05% 355
2017
Q3
$25.5M Buy
873,898
+42,724
+5% +$1.18M 0.03% 567
2017
Q2
$23M Buy
831,174
+185,347
+29% +$4.92M 0.02% 541
2017
Q1
$16.1M Buy
645,827
+286,715
+80% +$6.97M 0.02% 642
2016
Q4
$7.77M Buy
359,112
+132,745
+59% +$2.9M 0.01% 1084
2016
Q3
$5.39M Sell
226,367
-86,871
-28% -$2.07M 0.01% 1229
2016
Q2
$7.32M Sell
313,238
-199,907
-39% -$4.32M 0.01% 1035
2016
Q1
$9.24M Buy
513,145
+94,067
+22% +$1.65M 0.01% 804
2015
Q4
$7.54M Buy
419,078
+164,443
+65% +$2.95M 0.01% 1044
2015
Q3
$4.07M Sell
254,635
-292,523
-53% -$5M ﹤0.01% 1508
2015
Q2
$9.3M Sell
547,158
-478,066
-47% -$8.54M 0.01% 1081
2015
Q1
$17.4M Sell
1,025,224
-144,431
-12% -$2.28M 0.02% 764
2014
Q4
$15.2M Sell
1,169,655
-394,715
-25% -$5.05M 0.01% 913
2014
Q3
$17.2M Sell
1,564,370
-66,945
-4% -$843K 0.02% 815
2014
Q2
$19.6M Sell
1,631,315
-335,768
-17% -$4.37M 0.02% 712
2014
Q1
$25.6M Sell
1,967,083
-294,138
-13% -$3.86M 0.03% 563
2013
Q4
$27.1M Buy
2,261,221
+436,942
+24% +$5.16M 0.03% 598
2013
Q3
$20.1M Buy
1,824,279
+275,048
+18% +$2.98M 0.02% 670
2013
Q2
$14.4M Buy
+1,549,231
New +$13.1M 0.02% 830

Other funds holding BSX

Barclays's BSX Position: Q2 2026 in Review

Barclays reduced its Boston Scientific (BSX) stake by 8.8% in Q2 2026, selling an estimated $23.9M and leaving 4,584,260 shares worth $196M. The position accounts for 0.04% of the portfolio, ranked #306.

Barclays first reported a position in BSX in Q2 2013 and has held it in 53 quarters since. The position peaked at $558M in Q1 2025. 1,468 funds tracked by Wall St. Rank hold BSX as of Q2 2026.

  • Barclays held 4,584,260 shares of Boston Scientific worth $196M as of Q2 2026.
  • Barclays sold 439,897 Boston Scientific shares in Q2 2026, an estimated $23.9M.
  • Boston Scientific made up 0.04% of Barclays's portfolio in Q2 2026, its #306 holding.
  • Barclays first reported a position in Boston Scientific in Q2 2013 and has held it in 53 quarters since.
  • Barclays's Boston Scientific position peaked at $558M in Q1 2025.
  • 1,468 funds tracked by Wall St. Rank held Boston Scientific as of Q2 2026.

Based on Barclays's 13F filing for Q2 2026, filed 14 Aug 2026.